F8 and hemophilia A: Our data are similar to previous reports of real-world bleeding and FVIII use in individuals with severe haemophilia A. In a global, noninterventional study that prospectively collected real-world data of 49 participants with severe HA treated with prophylactic FVIII, the mean (95% confidence interval) and median (Q1, Q3) ABRs were 5.0 (3.3, 7.5) and 1.9 (0.0, 0.82) for treated bleeds and 6.2 (4.2, 9.2) and 2.7 (0.0, 9.4) for all bleeds, respectively; the majority (83.7%) of participants received SHL prophylaxis [18].